Monday, September 10, 2012

FDA Approves Myrbetriq...

“Myrbetriq (see below structure) is the first oral OAB treatment with a distinct mechanism of action since the launch of anticholinergic agents 30 years ago,” said Steven Ryder, MD, president, Astellas Pharma Global Development. “The approval of Myrbetriq represents an important milestone in OAB treatment and in our ongoing commitment to advancing urological health.”....



FDA_Approval_Press_Release_FINAL 6.28.12.pdf (application/pdf Object)

No comments:

Post a Comment